STADA and Alvotech broaden European patients’ options by launching Hukyndra® high-concentration, citrate-free adalimumab

[post] – Hukyndra® offers a comprehensive range of presentations to the EU adalimumab biosimilars market
– Adalimumab marks the first molecule introduced through STADA’s partnership with Alvotech to bring biosimilars across immunology, oncology and ophthalmology indications to patients and their caregivers in Europe
– Initial launch markets include France, Germany, Finland, and Sweden
STADA is offering Hukyndra®, the Alvotech-developed high-concentration, citrate-free formulation biosimilar of adalimumab to patients and their caregivers in selected European countries, including France, Germany, Finland, and Sweden. Launches in further European countries are scheduled over the coming months.
The biosimilar to Humira®, with its 100 mg/mL adalimumab in …

Read the source article at Trading For Keeps
2022-06-09 15:55:00